

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



1642  
#8/  
VC  
121801

<p>Application of</p> <p>Camellia W. Adams et al.</p> <p>Serial No.: 09/602,812</p> <p>Filed: June 23, 2000</p> <p>For: Humanized Anti-ErbB2 Antibodies and Treatment with Anti-ErbB2 Antibodies</p>	<p>Group Art Unit: 1642</p> <p>Examiner: J. Hunt</p> <hr/> <p><b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>October <u>30</u>, 2001</p> <p><u>Wm Lee</u></p> <p>Wendy M. Lee</p>
--	--

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement mailed October 2, 2001,  
Applicants elect group I claims 1-9, 12-13, 16-22, 24-29 and 34 without  
traverse.

Responsive to the species restriction detailed in the last paragraph on  
page 4, Applicants elect the species (B) of an antibody not conjugated  
with a cytotoxic agent. Group I claims readable on this species include  
claims 1-9, 12-13, 16-21, 24-29, and 34.

In relation to the further species restriction elaborated in the second  
paragraph on page 5 of the Office Action, Applicants elect (D) lung  
cancer. Group I claims readable on this species include claims 1-8, 12-  
13, 16-22, and 24-27.

Respectfully submitted,

GENENTECH, INC.

Date: October 30, 2001

By: Wm Lee

Wendy Lee

Reg. No. 40,378

Telephone No. (650) 225-1994



09157

PATENT TRADEMARK OFFICE

RECEIVED  
DEC 17 2001  
TECH CENTER 1800/2900